格菲妥单抗注射液致免疫相关心肌损伤1例分析

doi:10.19803/j.1672-8629.20250696

中国药物警戒 ›› 2026, Vol. 23 ›› Issue (2): 200-202.
DOI: 10.19803/j.1672-8629.20250696

格菲妥单抗注射液致免疫相关心肌损伤1例分析

于凌子¹, 贺嘉捷^1,2, 平娜娜¹, 朱倩¹, 张晓¹, 李俊红¹, 邹瑞¹, 何思蕴¹, 夏凡³, 金正明¹, 曲昌菊^1,*

¹苏州大学附属第一医院血液科，江苏苏州 215006;
²宁波市第六医院重症医学科，浙江宁波，315000;
³苏州大学附属第一医院药学部，江苏苏州 215006

收稿日期:2025-09-29 出版日期:2026-02-15 发布日期:2026-02-13
通讯作者: ^*曲昌菊，女，博士，副主任医师，淋巴瘤免疫治疗。E-mail: qcj310@163.com
作者简介:于凌子，女，本科，医师，临床医学。
基金资助:
苏州市科学技术局-双表观药物联合免疫化疗逆转弥漫大B细胞淋巴瘤耐药的应用基础研究（SKYD2023103）; 苏州工业园区和合远达血液创新研究院-表观调控肠道菌群靶向Smoothened致敏弥漫大B细胞淋巴瘤的机制研究（P112208523）; 北京市希思科临床肿瘤学研究基金会-双表观药物协同奥妥珠单抗调控Smoothened逆转弥漫大B细胞淋巴瘤化疗耐受性的机制研究（Y-SYBLD2022MS-0028）

One Case of Immune-Related Myocardial Injury Caused by Glofitamab Injection

YU Lingzi¹, HE Jiajie^1,2, PING Nana¹, ZHU Qian¹, ZHANG Xiao¹, LI Junhong¹, ZOU Rui¹, HE Siyun¹, XIA Fan³, JIN Zhengming¹, QU Changju^1,*

¹Department of Hematology, the First Affiliated Hospital of Soochow University, Suzhou Jiangsu 215006, China;
²Department of Intensive Care Unit, the Sixth Hospital of Ningbo, Ningbo Zhejiang 315000, China;
³Department of Pharmacy, the First Affiliated Hospital of Soochow University, Suzhou Jiangsu 215006, China

Received:2025-09-29 Online:2026-02-15 Published:2026-02-13

摘要/Abstract

摘要： 目的探讨格菲妥单抗致免疫相关心肌损伤的不良反应，为临床安全用药提供参考。方法对1例格菲妥单抗致弥漫大B细胞淋巴瘤患者免疫相关心肌损伤的病例进行分析，并结合相关文献进行总结。结果根据患者的临床表现、实验室检查及用药时间关联性，本例患者的免疫相关心肌损伤很可能与格菲妥单抗相关，给予地塞米松、托珠单抗、连续性肾脏替代治疗、曲美他嗪、瑞舒伐他汀及单硝酸异山梨酯等综合治疗后患者好转出院。结论格菲妥单抗致免疫相关心肌损伤发生率较低，但致死率较高。临床在应用格菲妥单抗治疗前应加强风险评估，用药期间密切监测，注意格菲妥单抗致免疫相关心肌损伤的风险。

关键词: 格菲妥单抗, 双特异性抗体, 弥漫大B细胞淋巴瘤, 细胞因子释放综合征, 免疫相关心肌损伤, 地塞米松, 连续性肾脏替代治疗, 药品不良反应

Abstract: Objective To investigate immune-related myocardial injury induced by glofitamab in order to provide a reference for safe clinical use. Methods Immune-related myocardial injury induced by glofitamab in a patient with diffuse large B-cell lymphoma was analyzed while related literature was summarized. Results Based on the patient’s clinical manifestations, results of laboratory tests, and the temporal association with drug administration, the immune-related myocardial injury was considered to be strongly associated with glofitamab. After comprehensive management involving dexamethasone, tocilizumab, continuous renal replacement therapy, trimetazidine, rosuvastatin, and isosorbide mononitrate, the patient improved and was discharged. Conclusion Despite the seemingly low incidence of glofitamab-induced immune-related myocardial injury, the associated mortality can be exceedingly high. Prior to glofitamab therapy, potential risks should be assessed, and during treatment, patients should be closely monitored for the risk of immune-related myocardial injury.

Key words: Glofitamab, Bispecific Antibody, Diffuse Large B-Cell Lymphoma, Cytokine Release Syndrome, Immune-related Myocardial Injury, Dexamethasone, Continuous Renal Replacement Therapy, Adverse Drug Reactions

中图分类号:

于凌子, 贺嘉捷, 平娜娜, 朱倩, 张晓, 李俊红, 邹瑞, 何思蕴, 夏凡, 金正明, 曲昌菊. 格菲妥单抗注射液致免疫相关心肌损伤1例分析[J]. 中国药物警戒, 2026, 23(2): 200-202.

YU Lingzi, HE Jiajie, PING Nana, ZHU Qian, ZHANG Xiao, LI Junhong, ZOU Rui, HE Siyun, XIA Fan, JIN Zhengming, QU Changju. One Case of Immune-Related Myocardial Injury Caused by Glofitamab Injection[J]. Chinese Journal of Pharmacovigilance, 2026, 23(2): 200-202.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20250696

https://zgywjj.magtechjournal.com/CN/Y2026/V23/I2/200

参考文献

[1] DICKINSON MJ, CARLO-STELLA C, MORSCHHAUSER F, et al.Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma[J]. N Engl J Med, 2022, 387(24): 2220-2231.
[2] SONG YQ, ZHANG HL, HUANG HQ, et al.Glofitamab Monotherapy Induces High Complete Response Rates and Manageable Safety in Chinese Patients with Heavily Pretreated Relapsed or Refractory Diffuse Large B-Cell Lymphoma[J]. Haematologica, 2024, 109(4): 1269-1273.
[3] SHUMILOV E, WURM-KUCZERA R, KERKHOFF A, et al.Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study[J]. Blood Adv, 2025, 9(15): 3865-3877.
[4] SAYED A, MUNIR M, GHAZI SM, et al.Cardiovascular Toxicities Associated with Bispecific T-Cell Engager Therapy[J]. J Immunother Cancer, 2024, 12(2): E008518.
[5] HUTCHINGS M, MORSCHHAUSER F, IACOBONI G, et al.Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: a Phase I Trial[J]. J Clin Oncol, 2021, 39(18): 1959-1970.
[6] LEE DW, SANTOMASSO BD, LOCKE FL, et al.ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells[J]. Biol Blood Marrow Transplant, 2019, 25(4): 625-638.
[7] CHEN PX, TANG Y, HE WX, et al.Potential Pathophysiological Mechanisms Underlying Multiple Organ Dysfunction in Cytokine Release Syndrome[J]. Mediators Inflamm, 2022, 2022: 7137900.
[8] MUNIR M, SAYED A, ADDISON D, et al.Cardiovascular Toxicities Associated with Novel Cellular Immune Therapies[J]. Blood Adv, 2024, 8(24): 6282-6296.
[9] MORRIS EC, NEELAPU SS, GIAVRIDIS T, et al.Cytokine Release Syndrome and Associated Neurotoxicity in Cancer Immunotherapy[J]. Nat Rev Immunol, 2021, 22(2): 85-96.
[10] ALVI RM, FRIGAULT MJ, FRADLEY MG, et al.Cardiovascular Events among Adults Treated with Chimeric Antigen Receptor T-Cells (CAR-T)[J]. J Am Coll Cardiol, 2019, 74(25): 3099-3108.
[11] LIU L, YAO WT, WANG M, et al. A Systematic Review of Cardiovascular-Toxicities Induced by Cancer Immune Therapies: Underlying Mechan-isms, Clinical Manifestations and Therapeutic Approaches[J]. Semin Cancer Biol, 2024, 106-107: 179-191.
[12] SHALABI H, SACHDEV V, KULSHRESHTHA A, et al.Impact of Cytokine Release Syndrome on Cardiac Function Following CD19 CAR-T Cell Therapy in Children and Young Adults with Hematological Malignancies[J]. J Immunother Cancer, 2020, 8(2): E001159.
[13] CROMBIE JL, GRAFF T, FALCHI L, et al.Consensus Recommen-dations on the Management of Toxicity Associated with CD3×CD20 Bispecific Antibody Therapy[J]. Blood, 2024, 143(16): 1565-1575.
[14] CONSTANTINESCU C, PASCA S, TAT T, et al.Continuous Renal Replacement Therapy in Cytokine Release Syndrome Following Immunotherapy or Cellular Therapies?[J]. J Immunother Cancer, 2020, 8(1): E000742.
[15] SRINIVASAN SRIDHAR V, CHEN M, GERSON H, et al.Variation of High-Sensitivity Troponin T Results in Patients Undergoing Continuous Renal Replacement Therapy[J]. Can J Kidney Health Dis, 2019, 6: 2054358119828386.

格菲妥单抗注射液致免疫相关心肌损伤1例分析

One Case of Immune-Related Myocardial Injury Caused by Glofitamab Injection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	王春婷, 张瑞芳, 陈亚飞. 盐酸雷尼替丁注射制剂安全性风险分析[J]. 中国药物警戒, 2026, 23(2): 181-184.
[2]	田春雨, 夏玉朝, 张艳华, 尹月. 达拉非尼胶囊联合曲美替尼片致发热综合征的分析[J]. 中国药物警戒, 2026, 23(2): 192-196.
[3]	江文豪, 徐红冰, 张小刚, 吴江平. 盐酸胺碘酮注射液致急性肝衰竭1例分析[J]. 中国药物警戒, 2026, 23(2): 197-199.
[4]	刘甜甜, 靳梦亚, 赵雪, 巩颖, 张彦丽, 曹俊岭. 注射用美罗培南与伏立康唑联用致严重精神障碍1例分析[J]. 中国药物警戒, 2026, 23(2): 203-206.
[5]	孟德辉, 王超, 李华, 丁春雷. 替吉奥胶囊致胃癌患者重症间质性肺炎1例分析[J]. 中国药物警戒, 2026, 23(2): 207-209.
[6]	吴晓平, 张永良. 盐酸莫西沙星片与伏立康唑片联用致周围神经病变1例分析[J]. 中国药物警戒, 2026, 23(2): 210-212.
[7]	丁姝文, 马瑞泽, 陈志海. 球孢子菌病抗真菌药物研究进展[J]. 中国药物警戒, 2026, 23(2): 224-228.
[8]	王丽, 邬静, 李敏, 袁嘉欣, 于文雯, 戚迎梅. 降脂药物研究进展[J]. 中国药物警戒, 2026, 23(2): 235-240.
[9]	兰晓倩, 庄红艳, 李鹏飞. 183例抗精神病药致锥体外系反应报告分析[J]. 中国药物警戒, 2026, 23(1): 101-104.
[10]	周炜, 王利媛, 王芳, 孙艳艳, 夏一淼, 王法财. 英夫利昔单抗和乌司奴单抗致肺结核1例分析[J]. 中国药物警戒, 2026, 23(1): 105-108.
[11]	王媛慧, 张清, 李歆, 苏钰文. 慢性乙型肝炎抗病毒治疗安全性研究进展[J]. 中国药物警戒, 2026, 23(1): 115-119.
[12]	蒋晓峰, 杨淑婷, 白丽琴, 戚俊, 何建雄, 陈文戈, 梁祖红, 李渔, 余晓霞. 医疗机构制剂不良反应监测与评价系统构建及初步实践[J]. 中国药物警戒, 2025, 22(9): 1008-1011.
[13]	蔡杰, 韩陈媛, 江君微. 887例静脉滴注抗菌药物不良反应报告分析[J]. 中国药物警戒, 2025, 22(9): 1018-1023.
[14]	郑金凤, 吴佳妮, 林京玉, 杨雪卿. 222例口服凝血因子Xa抑制剂不良反应报告分析[J]. 中国药物警戒, 2025, 22(9): 1024-1028.
[15]	谢加力, 荀艳, 陶云松, 章圣朋. 211例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(9): 1029-1033.